Keywords: |
human tissue; unclassified drug; gene mutation; human cell; major clinical study; mutation, missense; histopathology; carcinoma, squamous cell; neoplasm staging; protein domain; adenocarcinoma; protein analysis; risk factors; fibroblast growth factor receptor 3; dna sequence; heterozygosity loss; codon; uterine cervical neoplasms; chromosome 3p; chromosome 11q; uterine cervix carcinoma; chromosome 5p; chromosome 17p; chromosome 18q; chromosome 19q; fibroblast growth factor receptor; chromosome 6p; receptors, fibroblast growth factor; chromosome 4p; humans; human; female; priority journal; article
|